

Clinical Policy: Intensity-Modulated Radiotherapy

Reference Number: LA.CP.MP.69

[Implications](#)

[Coding](#)

Date of Last Revision: ~~05/24~~03/25

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Medical necessity criteria for intensity-modulated radiotherapy (IMRT). IMRT is ~~an advanced form of 3-dimensional (3-D)~~ a technology that delivers highly conformal external beam radiation therapy that delivers a more precise to specified targets with radiation dose to beams whose intensity varies throughout the tumor while sparing healthy surrounding tissue.¹ ~~While treatment fields, IMRT empirically offers advances over other radiation therapies, accepted practices and the risks and benefits of IMRT over conventional or 3-D is useful for delivery of highly conformal radiation~~ ~~must~~ doses to targets positioned near sensitive normal tissues. The treatment planning for IMRT is a multi-step process, one of which is contouring for defining the target and avoiding normal structures that could potentially be considered ~~—harmed by radiation.~~⁴⁷

Policy/Criteria

- I. It is the policy of Louisiana Healthcare Connections that IMRT is **medically necessary** for **any** of the following indications:
 - ~~A.~~ Age \leq 18 years;
 - ~~B.~~ Target volume is in close proximity to critical structures that must be protected;
 - ~~C.~~ ~~A.~~ The volume of interest must be covered with narrow margins to adequately protect immediately adjacent structures; a solid tumor;
 - ~~D.~~ An immediately adjacent area has been previously irradiated and abutting portals must be established Medically inoperable patient with high precision;
 - ~~E.~~ The target volume is concave or convex, and critical normal tissues are within or around that convexity or concavity;
 - ~~F.~~ ~~B.~~ Dose diagnosis of cancer where dose escalation is planned to deliver radiation doses in excess of those commonly utilized for similar tumors with conventional treatment; required;⁴⁷
 - ~~C.~~ Primary malignant or benign bone tumors;⁴⁷
 - ~~D.~~ Re-irradiation (where cumulative critical structure dose would exceed tolerance dose);⁴⁷
 - ~~G.~~ ~~E.~~ Indications by cancer site may include any of the following:
 - ~~1.~~ Primary or benign tumor(s) of the central nervous system, including brain, brain stem, and spinal cord;
 - ~~2.~~ Primary tumor(s) of the spine where spinal cord tolerance may be exceeded by conventional treatment;
 - ~~3.~~ Primary or benign lesion(s) of the head and neck area including orbits, sinuses, skull base, aerodigestive tract (lips, mouth, tongue, tonsils, nose, throat, vocal cords and part of the trachea and esophagus), salivary glands, and thyroid;
 - ~~4.~~ Anal or perianal cancer, excluding locally recurrent perianal cancer;
 - ~~5.~~ Prostate cancer, definitive (curative) treatment;
 - ~~6.~~ Vulvar cancer, definitive (curative) treatment;
 - ~~7.~~ 1. Cervical cancer, curative treatment Central Nervous System, any of the following:⁴⁷

- ~~a. Post hysterectomy;~~
- ~~a. For treatment~~Ocular tumors, including intraocular melanomas;
- ~~b. Tumors that includes para-aortic nodes;~~
- ~~e.b. For high doses of radiation in approach or are located at the presence of gross disease in regional lymph nodes~~base of skull;
- ~~c. Select breast cancer cases~~Primary CNS tumors, primary spine, or metastatic tumors to the spine or spinal cord where organ at risk tolerance may be exceeded with 3-D conformal treatments;
- ~~d. Primary and metastatic tumors requiring craniospinal irradiation;~~
- ~~e. Brain metastases requiring hippocampal-sparing whole brain radiotherapy;~~
- ~~8.2. Head and Neck, any of the following:~~⁴⁷
 - ~~a. Homogeneity of dose cannot be achieved with conventional three-dimensional planning techniques;~~
 - ~~b. Left-sided breast cancers when treating the internal mammary lymph nodes;~~
 - ~~a. When~~Definitive, adjuvant, or palliative treatment of primary/secondary head and neck cancers or draining lymphatics of the neck including (but not limited to) cancers of the nasopharynx, nasal cavity, paranasal sinuses, oropharynx, oral cavity, hypopharynx, larynx, thyroid, or salivary glands;
 - ~~b. Cutaneous tumors with cranial nerve invasion to the base of skull, cavernous sinus, and/or brainstem;~~
 - ~~c. Mucosal Melanoma;~~
 - ~~d. Occult (or unknown) primary malignancies of the head and neck;~~
- ~~3. Breast, any of the following:~~⁴⁷
 - ~~a. Bilateral breast cancers requiring nodal treatment on at least one side;~~
 - ~~b. Breast cancer patients being treated with definitive intent and who have unfavorable anatomy (e.g., pectus excavatum) that would deliver unacceptably high doses to organs-at-risk;~~
 - ~~c. Early-stage breast cancer in which dose to the heart is unacceptably high with conventional photon or photon/electron using external beam accelerated~~cardiac sparing techniques;
 - ~~a.d. Accelerated partial breast irradiation (APBI);~~, regardless of laterality;
- ~~9. Uterine neoplasms;~~
- ~~10. Pancreatic cancer;~~
- ~~11. Stage III non-small cell lung cancer;~~
- ~~12. Esophageal cancer;~~
 - ~~e. Mediastinal~~Patients in whom internal mammary lymph nodes are targeted;
 - ~~f. Breast cancer patients who have limited ipsilateral arm range of motion and require treatment in the arms down position;~~
 - ~~g. Post-mastectomy radiotherapy when the patient has had bilateral implant-based reconstruction;~~
 - ~~h. Whole breast radiotherapy in patients with bilateral augmentation implants;~~
- ~~4. Thoracic, any of the following:~~⁴⁷
 - ~~a. Primary or secondary tumors (e.g., of the mediastinum, including thymic tumors, mediastinal tumors, mediastinal lymphomas and thymomas);~~thoracic sarcomas;
 - ~~b. Early-stage lung cancer for which SBRT is not feasible secondary to anatomic considerations;~~

- c. Locally advanced lung cancer in which IMRT significantly reduces dose to normal tissues (ex: bilateral mediastinal disease, paraspinal tumors, N3 disease, reducing esophageal dose);
- d. Malignant pleural mesothelioma;
- 5. Gastrointestinal, any of the following:⁴⁷
 - a. Hepatocellular cancer, bile duct, gallbladder and cholangiocarcinoma cancers;
 - b. Primary cancers of the esophagus and GE junction;
 - c. Abdominal malignancies, including primary pancreatic, gastric and adrenal incancers;
 - d. Primary and Secondary liver cancers;
 - e. Anal and colorectal cancers;
- 6. Sarcomas, any of the following:⁴⁷
 - a. Retroperitoneal sarcomas;
 - b. Desmoid tumors;
 - c. Endometrial cancer;
- 7. Pelvic/Gynecological, any of the following:⁴⁷
 - a. Cervical cancer;
 - b. Vulvar and vaginal cancers;
 - b.c. Endometrial cancer;
- 8. ~~Select rectal~~Genitourinary, any of the following:⁴⁷
 - a. Prostate cancer-eases;
 - b. Renal cancer;
 - c. Bladder cancer;
 - d. Penile cancer;
 - e. Ureteral cancer;

Note: The above indications are anatomical sites reported by ASTRO where thereIMRT is lymph node involvement or require treatment of the inguinal lymph nodes;commonly performed, but may not be an all-inclusive listing.⁴⁷

~~13. Soft tissue sarcoma when organ at risk dose constraints cannot be met.~~

Background

~~A major goal of radiation therapy is the delivery of an appropriate dose of radiation to the targeted tissue while minimizing radiation exposure to the surrounding healthy tissue. The introduction of intensity modulated radiotherapy (IMRT) allows for significant improvement of dose distributions by irradiating sub-regions of the target to different levels. It uses a computer-based planning method called inverse planning that allows the delivery of generally narrow, patient specific, spatially and often temporally modulated beams of radiation to solid tumors within a patient.⁴~~

IMRT changes the intensity of radiation in different parts of a single radiation beam while treatment is delivered. The dose of radiation given by each beam can also vary, enabling IMRT to simultaneously treat multiple areas within the target to different dose levels. Theoretical concerns about IMRT include dose inhomogeneity, additional time required for planning

computation and quality assurance (QA) verification, and exposure of larger volumes of normal tissues to a lower dose of radiation.¹⁻²⁻³

There were numerous studies done, including a multicenter, randomized, double-blind trial that indicated IMRT improved the homogeneity of the radiation dose distribution and decreased acute toxicity, when used for breast cancer.⁴⁻⁸³⁻⁷

OMRT and volumetric-modulated arc therapy (VMAT) are the standard of care for treatment of many pediatric cancers. Many are under investigation such as stereotactic body radiation therapy (SBRT) for treating bone tumors, along with metastatic and recurrent lesions.⁴⁸

The National Comprehensive Cancer Network (NCCN) recommends IMRT in a number of cancer types, including cancers whose radiation treatment may affect organs or other critical structures at risk.

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted ~~2023~~2024, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only and may not support medical necessity. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

NOTE: Coverage is subject to each requested code’s inclusion on the corresponding LDH fee schedule. Non-covered codes are denoted (*) and are reviewed for Medical Necessity for members under 21 years of age on a per case basis.

CPT® Codes	Description
77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex

HCPCS Codes	Description
G6015*	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session
G6016*	Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Converted corporate to local policy.	12/1/2020	
Annual review. References reviewed and updated. Reviewed by specialist. Changed <u>"Last Review Date"</u> in the header to <u>"Date of Last Revision"</u> and <u>"Date"</u> in revision log to <u>"Revision Date"</u> . Added "and may not support medical necessity" to coding implications".	2/22	
<u>Annual review completed.</u> Background updated. ICD-10 code table removed. <u>References reviewed and updated.</u>	1/23	4/10/23
Annual review. Added Criteria I.G.9. uterine neoplasms. Added Criteria I.G.10. pancreatic cancer. Added Criteria I.G.11. stage III non-small cell lung cancer. Background updated with no impact on criteria. References reviewed and updated. Reviewed by external specialist. Note for non-covered codes added.	09/23	11/27/23
Annual review. Removed I.G.8.a.i-iii regarding "maximum dose volume", "volume of breast tissue", and "hot spots in inframammary fold", leaving I.G.8.a. regarding "homogeneity of dose". Changed I.G.8.b. to "Left-sided breast cancers when treating the internal mammary lymph nodes", and I.G.8.c. to "When using external beam accelerated partial breast irradiation (APBI)". Added additional indications to criteria I.G.12 Esophageal cancer, I.G.13. Mediastinal tumors (e.g., lymphomas and thymomas); I.G.14. Endometrial cancer; I.G.15. Select rectal cancer cases where there is lymph node involvement or require treatment of the inguinal lymph nodes; I.G.16. Soft tissue sarcoma when organ at risk dose constraints cannot be met. References reviewed and updated.	05/24	7/16/24
<u>Annual review. Edits to description and background with no impact on criteria. Removed I.B - G, leaving I.A. "Age < 18 years". Added I.B. "Medically inoperable.....required"; added I.C. "Primary malignant....tumors"; added I.D. "Re-irradiation (where.....dose)"; added I.E.1 - 8, all new indications by cancer site. Added note "The above indications.....all-inclusive listing". References reviewed and updated. Reviewed by external specialist.</u>	<u>3/25</u>	

References

1. ~~Local coverage determination (L36711). Centers for Medicare and Medicaid Services Web site. <http://www.cms.hhs.gov/med/search.asp>. Published December 1, 2016 (revised January 01, 2021). Accessed March 8, 2024.~~
2. ~~1.~~ Koyfman SA. General principles of radiation therapy for head and neck cancer. UpToDate. www.uptodate.com. Updated October 30, 2023. Accessed ~~March 8, 2024~~ January 3, 2025.
3. ~~2.~~ Mitin T. Radiation therapy techniques in cancer treatment. UpToDate. www.uptodate.com. Updated March 16, 2023. Accessed ~~March 8, 2024~~ January 3, 2025.
4. ~~3.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~2.2023~~ 1.2025 Uterine Neoplasms. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Updated ~~March 6~~ December 16, 2024. Accessed ~~March 8~~ December 27, 2024.
5. ~~4.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~1.2023~~ 4.2024 Vulvar Cancer. https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf. Updated ~~December 31, 2023~~ https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf. Updated May 1, 2024. Accessed ~~March 8~~ December 27, 2024.
6. ~~5.~~ National Cancer Institute (NCI). ATC guidelines for use of IMRT (including intra-thoracic treatments). May 2006. Accessed ~~March 8~~ December 27, 2024.
7. ~~6.~~ Donovan E, Bleakley N, Denholm E, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. *Radiother Oncol*. 2007;82(3):254 to 264. ~~Doi~~ doi:10.1016/j.radonc.2006.12.008
8. ~~7.~~ McDonald MW, Godette KD, Butker EK, Davis LW, Johnstone PA. Long-term outcomes of IMRT for breast cancer: a single-institution cohort analysis. *Int J Radiat Oncol Biol Phys*. 2008;72(4):1031 to 1040. ~~Doi~~ doi:10.1016/j.ijrobp.2008.02.053
9. ~~8.~~ Gebhardt MC, Baldini EH, Ryan CW. Overview of multimodality treatment for primary soft tissue sarcoma of the extremities and superficial trunk. UpToDate. www.uptodate.com. Updated ~~February 22, 2023~~ June 28, 2024. Accessed ~~March 8, 2024~~ January 3, 2025.
10. ~~9.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~4.2023~~ 6.2024 Breast cancer. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Updated ~~January 25~~ November 11, 2024. Accessed ~~March 8, 2024~~ January 2, 2025.
11. ~~10.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~1.2023~~ 2025 Cervical Cancer. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Updated ~~February 23~~ December 19, 2024. Accessed ~~March 8, 2024~~ January 2, 2025.
12. ~~11.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~1.2023~~ 2025 Prostate Cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Updated ~~March 8~~ December 4, 2024. Accessed ~~March 8, 2024~~ January 2, 2025.
13. ~~12.~~ Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. *JAMA*. 2012;307(15):1611 to 1620. ~~Doi~~ doi:10.1001/jama.2012.460
14. ~~13.~~ Staffurth J; Radiotherapy Development Board. A review of the clinical evidence for intensity-modulated radiotherapy. *Clin Oncol (R Coll Radiol)*. 2010;22(8):643 to 657. ~~Doi~~ doi:10.1016/j.clon.2010.06.013
15. ~~14.~~ Su JM. Intracranial germ cell tumors. UpToDate. www.uptodate.com. Updated ~~May~~ April 19, ~~2023~~ 2024. Accessed ~~March 8, 2024~~ January 3, 2025.
16. ~~Synderman C. Chordoma and chondrosarcoma of the skull base. UpToDate. www.uptodate.com. Updated February 27, 2024. Accessed March 8, 2024.~~

- ~~17.15.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~1.20233.2024~~ Central Nervous System Cancers. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Updated ~~March 24, 2023, September 30, 2024~~. Accessed ~~March 8, 2024~~[January 2, 2025](#).
- ~~18.16.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~2.20231.2025~~ Anal Carcinoma. https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf. Updated December ~~20, 20234, 2024~~. Accessed ~~March 8, 2024~~[January 2, 2025](#).
- ~~19.17.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~1.20235.2024~~ Gastric Cancer. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Updated ~~March 7~~[December 20, 2024](#). Accessed ~~March 8, 2024~~[January 2, 2025](#).
- ~~20.18.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~2.20231.2025~~ Head and Neck Cancers (~~Version 2.2022~~). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Updated ~~February 29, 2024~~[January 17, 2025](#). Accessed ~~March 8, 2024~~[January 21, 2025](#).
- ~~21.19.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~2.20234.2024~~ Thyroid Carcinoma. https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Updated ~~February 1~~[August 19, 2024](#). Accessed ~~March 8, 2024~~[January 2, 2025](#).
- ~~22.20.~~ DiBiase SJ, Roach M. External beam radiation therapy for localized prostate cancer. UpToDate. www.uptodate.com. Updated ~~October 5, 2023~~[November 7, 2024](#). Accessed ~~March 8, 2024~~[January 3, 2025](#).
- ~~23.21.~~ Galloway T, Amdur RJ. Management and prevention of complications during initial treatment of head and neck cancer. UpToDate. www.uptodate.com. Updated ~~October 25, 2023~~[August 1, 2024](#). Accessed ~~March 8, 2024~~[January 6, 2025](#).
- ~~24.22.~~ Gray HJ. Adjuvant treatment of intermediate-risk endometrial cancer. UpToDate. www.uptodate.com. Updated ~~October 30, 2023~~[July 31, 2024](#). Accessed ~~March 8, 2024~~[January 6, 2025](#).
- ~~25.23.~~ Karajannis MA, Marcus KJ. Focal brainstem glioma. UpToDate. www.uptodate.com. Updated ~~March 20, 2023~~[September 24, 2024](#). Accessed ~~March 8, 2024~~[January 6, 2025](#).
- ~~26.24.~~ MacKay RI, Staffurth J, Poynter A, Routsis D; Radiotherapy Development Board. UK guidelines for the safe delivery of intensity-modulated radiotherapy. *Clin Oncol (R Coll Radiol)*. 2010;22(8):629 to 635. ~~Doi~~[doi](https://doi.org/10.1016/j.clon.2010.06.017):10.1016/j.clon.2010.06.017
- ~~27.25.~~ Pignol JP, Olivetto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. *J Clin Oncol*. 2008;26(13):2085 to 2092. ~~Doi~~[doi](https://doi.org/10.1200/JCO.2007.15.2488):10.1200/JCO.2007.15.2488
- ~~28.26.~~ Rusthoven KE, Carter DL, Howell K, et al. Accelerated partial-breast intensity-modulated radiotherapy results in improved dose distribution when compared with three-dimensional treatment-planning techniques. *Int J Radiat Oncol Biol Phys*. 2008;70(1):296 to 302. ~~Doi~~[doi](https://doi.org/10.1016/j.ijrobp.2007.08.047):10.1016/j.ijrobp.2007.08.047
- ~~29.~~ ~~Local coverage determination: intensity modulated radiation therapy (IMRT) (L36773).~~ Centers for Medicare and Medicaid Services Web site. <http://www.cms.hhs.gov/med/search.asp>. Published November 07, 2016. (revised July 31, 2019). Accessed ~~March 8, 2024~~.
- ~~30.27.~~ Dagan R, Amdur RJ, Yeung AR, Dziegielewska PT. Tumors of the nasal cavity. UpToDate. www.uptodate.com. Updated ~~March 14, 2023~~. Accessed ~~March 8, 2024~~[January 6, 2025](#).

- ~~31-28.~~ Chino J, Annunziata CM, Beriwal S, et al. Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Pract Radiat Oncol.* 2020;10(4):220 to 234. ~~Doi:10.1016/j.prro.2020.04.002~~
- ~~32-29.~~ Hui EP, Chan AT, Le QT. Treatment of early and locoregionally advanced nasopharyngeal carcinoma. UpToDate. www.uptodate.com. Updated ~~September 12, 2023~~November 7, 2024. Accessed ~~March 8, 2024~~January 7, 2025.
- ~~33-30.~~ Ryan DP, Willett CG. Treatment of anal cancer. UpToDate. www.uptodate.com. Updated July 24, 2023. Accessed ~~March 8, 2024~~January 7, 2025.
- ~~34-31.~~ Loeffler JS. Overview of the treatment of brain metastases. UpToDate. www.uptodate.com. Updated ~~November 29, 2023~~22, 2024. Accessed ~~March 8, 2024~~January 7, 2025.
- ~~35-32.~~ Peikert T, Owen D. Radiation-induced lung injury. UpToDate. www.uptodate.com. Updated September 26, 2023. Accessed ~~March 8, 2024~~January 7, 2025.
- ~~36-33.~~ Marks LB, Constine LS, Adams MJ. Cardiotoxicity of radiation therapy for breast cancer and other malignancies. UpToDate. www.uptodate.com. Updated December ~~13, 2023~~5, 2024. Accessed ~~March 8, 2024~~January 7, 2025.
- ~~37-34.~~ Butler-Xu YS, Marietta M, Zahra A, TenNapel M, Mitchell M. The effect of breast volume on toxicity using hypofractionated regimens for early stage breast cancer for patients. *Adv Radiat Oncol.* 2018;4(2):261 to 267. Published 2018 Nov 1. ~~Doi:10.1016/j.adro.2018.10.005~~
- ~~38-35.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~2-2023~~1.2025. Pancreatic Adenocarcinoma. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Updated December ~~13, 2023~~20, 2024. Accessed ~~March 8, 2024~~January 2, 2025.
- ~~39-36.~~ Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. *Eur J Cancer.* 2015;51(4):451 to 463. ~~Doi:10.1016/j.ejca.2014.12.013~~
- ~~40-37.~~ Meattini I, Marrazzo L, Saieva C, et al. Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial. *J Clin Oncol.* 2020;38(35):4175 to 4183. ~~Doi:10.1200/JCO.20.00650~~
- ~~41-38.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~3-2023~~1.2025. Non-Small Cell Lung Cancer. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Updated ~~February 9~~December 20, 2024. Accessed ~~March 8, 2024~~January 2, 2025.
- ~~42-39.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version ~~15~~.2024. Esophageal and Esophagogastric Junction Cancers. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Updated ~~March 7~~December 20, 2024. Accessed ~~March 18, 2024~~January 2, 2025.
- ~~43-40.~~ National Comprehensive Cancer Network®. NCCN Guidelines Version 1.~~2024~~2025. Thymomas and Thymic Carcinomas. https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf Updated ~~November 21, 2023~~October 30, 2024. Accessed ~~March 18, 2024~~January 2, 2025.

- 44.41. National Comprehensive Cancer Network®. NCCN Guidelines Version ~~2.2024~~1.2025. T-Cell Lymphomas. https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Updated ~~March 14~~November 11, 2024. Accessed ~~March 18, 2024~~January 2, 2025.
- 45.42. American College of Radiology End User License Agreement. Accessed ~~March 18, 2024~~January 2, 2025. <https://acsearch.acr.org/docs/3097398/Narrative>
- 46.43. National Comprehensive Cancer Network®. NCCN Guidelines Version ~~14.~~2024 Rectal Cancer. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Updated ~~January 29~~August 22, 2024. Accessed ~~March 28, 2024~~January 2, 2025.
44. National Comprehensive Cancer Network®. NCCN Guidelines Version ~~3.2023~~4.2024 Soft Tissue Sarcoma. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Updated ~~December 12, 2023.~~ Accessed ~~March 28, 2024.~~ Updated November 21, 2024. Accessed January 2, 2025.
45. Iyengar P, All S, Berry MF, et al. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. *Pract Radiat Oncol.* 2023;13(5):393-412. doi:10.1016/j.prro.2023.04.004
46. Harkenrider MM, Abu-Rustum N, Albuquerque K, et al. Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline. *Pract Radiat Oncol.* 2023;13(1):41-65. doi:10.1016/j.prro.2022.09.002
47. ASTRO Model Policies- Intensity Modulated Radiation Therapy (IMRT). <https://www.astro.org/ASTRO/media/ASTRO/Daily%20Practice/PDFs/IMRTMP.pdf>. Accessed January 22, 2025.
48. Hua CH, Mascia AE, Seravalli E, Lomax AJ, Seiersen K, Ulin K. Advances in radiotherapy technology for pediatric cancer patients and roles of medical physicists: COG and SIOP Europe perspectives. *Pediatr Blood Cancer.* 2021 May;68 Suppl 2(Suppl 2): e28344. doi: 10.1002/pbc.28344. PMID: 33818892; PMCID: PMC8030241.
49. National Comprehensive Cancer Network®. NCCN Guidelines Version 1.2025 Hodgkin Lymphoma. https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Updated December 24, 2024. Accessed January 27, 2025.
50. National Comprehensive Cancer Network®. NCCN Guidelines Version 1.2025 B-Cell Lymphomas. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Updated December 20, 2024. Accessed January 27, 2025.

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering

benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

©2024 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademarks exclusively owned by Louisiana Healthcare Connections.